Catalog No.
DHD03701
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
SF, HPTA, Hepatopoietin-A, Hepatocyte growth factor, Scatter factor, HGF
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P14210
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AV-299, SCH 900105, CAS: 1174900-84-5
Clone ID
Ficlatuzumab
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases, PMID: 24634378
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer, PMID: 28209746
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma, PMID: 27448761
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer, PMID: 33725344
Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer, PMID: 27569653
C-MET inhibitors in the treatment of lung cancer, PMID: 25266653
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer, PMID: 23493885
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs, PMID: 25217525
Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab, PMID: 26540318
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC, PMID: 29346833
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma, PMID: 24901237
Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer, PMID: 32545260
Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI, PMID: 23983258
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib, PMID: 23715581
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors, PMID: 27831000
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer, PMID: 33638808
Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma, PMID: 30636579
The emerging role of MET/HGF inhibitors in oncology, PMID: 23453860
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer., PMID:36977289
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer., PMID:36807743
Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis., PMID:36716856
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis., PMID:34514432
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer., PMID:33725344
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer., PMID:33638808
Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer., PMID:32545260
Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma., PMID:30636579
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC., PMID:29346833
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer., PMID:28209746
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors., PMID:27831000
Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer., PMID:27569653
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma., PMID:27448761
Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab., PMID:26540318
C-MET inhibitors in the treatment of lung cancer., PMID:25266653
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs., PMID:25217525
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma., PMID:24901237
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases., PMID:24634378
Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI., PMID:23983258
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib., PMID:23715581
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer., PMID:23493885
The emerging role of MET/HGF inhibitors in oncology., PMID:23453860
For research use only. Not for human or drug use.
